Login / Signup

Primary prophylaxis with G-CSF for patients with non-round cell soft tissue sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology.

Takeshi HiroseMamoru ItoKenji TsuchihashiYukinori OzakiHiroshi NishioEiki IchiharaYuji MiuraShingo YanoDai MaruyamaTetsuhiro YoshinamiNobuyuki SusumuMunetaka TakekumaTakashi MotohashiEishi BabaNobuaki OchiToshio KuboKeita UchinoTakahiro KimuraYutaro KamiyamaShinji NakaoShinobu TamuraHitomi NishimotoYasuhisa KatoAtsushi SatoToshimi TakanoMakoto Endo
Published in: International journal of clinical oncology (2024)
The clinical questions were converted to future research questions because of insufficient available data. The statements were proposed: "The benefit of primary G-CSF prophylaxis is not clear in NRC-STS" and "The benefit of intensified chemotherapy with primary G-CSF prophylaxis is not clear in NRC-STSs." G-CSF is often administered as primary prophylaxis when chemotherapy with severe myelosuppression is administered. However, its effectiveness and safety are yet to be scientifically proven.
Keyphrases
  • soft tissue
  • cerebrospinal fluid
  • stem cells
  • radiation therapy
  • machine learning
  • high grade
  • cell therapy
  • electronic health record
  • artificial intelligence
  • rectal cancer